Notably, aberrant overexpression of PODXL has been documented across a wide spectrum of human malignancies, including pancreatic ductal adenocarcinoma (PDAC) [7], renal cell carcinoma [8], colorectal cancer [9], breast cancer [10], and oral squamous cell carcinoma [11]. Here, PODXL is linked to renal cell carcinoma.